Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Solventum (SOLV) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareMedical Instruments & SuppliesSOLV

Closing price · Nov 19, 2026 $85.49 -1.1% on the day · +10.6% over 12 months 52-week range $62.49 – $92.44
Get SOLV alerts
Open-market purchases1 insider$100K · last 12 months
Insiders selling0last 12 months
Reported sales$0last 12 months
In 15 seconds

Insiders put their own money in: $100K of open-market buys. See how similar setups did below.

Past insider buys here: 1 of 1 beat the S&P 500 over the next 90 days (small sample). See each one ↓

Label: Net buying · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
Latest open-market trade

Purchase Amy McBride Wendell, Director bought 1,475 shares at $68.03 ($100K).

Trade date
Mar 10, 2026
Disclosed to the SEC
Mar 11, 2026
Type
Open-market purchase (code P)

Amy McBride Wendell's record since 2023: 1 of 1 past buy beat the S&P 500 over 90 days (small sample).

Read the original SEC filing ↗All SOLV insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

SOLV insider transactions (Form 4)

Open-market purchases and sales. 64 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Mar 11SEC Amy McBride WendellDirectorFirst buy Buy 1,4755,039 held (+41%) $68.03 $100K +25.7% —
Historical context

Similar past setups: not applicable. There aren't enough comparable past cases for SOLV's latest buying to report odds. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with SOLV in the Research Lab

Pre-set to SOLV's latest insider buy of $10K or more (Mar 11, 2026: Amy McBride Wendell, $100K). Tap to change anything.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

SOLV closeInsider buyInsider sale
60708090100DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-26EEarnings release filed 2026-05-05EEarnings release filed 2026-08-05Bought $100,344 on 2026-03-10 · Amy McBride Wendell
Bought, 12 months$100K
Sold, 12 months$0
Insiders buying1
Insiders selling0

Solventum insider trading at a glance (Nov 20, 2026): in the past 12 months, 1 insider bought $100K and 0 sold $0 of SOLV stock on the open market; P/E 99.8 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

SOLV insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q1 2026: $100K bought (1 trades)$100KQ1 2026Q2 2026Q3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026—0—0
Q2 2026—0—0
Q1 2026$100K1—0

Valuation, profit and volume

P/E (trailing)99.8Sector median 25.0
Market value$15.10BMedical Instruments & Supplies
Profit margin1.9%Revenue growth -7.0%
Volume vs. 50-day0.6×Last 5 sessions
Insiders' paper profit+$26KOn all tracked purchases +25.7%

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 1 Solventum insider reported open-market purchases totaling $100K, while 0 insiders reported sales totaling $0.

SOLV earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Aug 5, 2026 +11.0% None -5.7%S&P -0.4% +10.5%
May 5, 2026 -4.3% None +5.3%S&P +2.2% +14.1%
Feb 26, 2026 -6.7% None -1.2%S&P -1.0% -15.4%
Nov 6, 2025 -7.2% None +5.7%S&P -1.0% +19.4%
Aug 7, 2025 -0.5% None +1.1%S&P +0.7% -0.9%
May 8, 2025 +0.8% None +7.2%S&P +0.6% +6.6%
Feb 27, 2025 +14.1% None -5.1%S&P -0.1% -6.3%
Nov 7, 2024 +2.1% None -2.3%S&P +1.2% -3.4%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

SOLV short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 50% of volume sold short2026-08-27: 63% of volume sold short2026-08-28: 62% of volume sold short2026-08-31: 64% of volume sold short2026-09-01: 63% of volume sold short2026-09-02: 65% of volume sold short2026-09-03: 57% of volume sold short2026-09-04: 53% of volume sold short2026-09-08: 66% of volume sold short2026-09-09: 74% of volume sold short2026-09-10: 59% of volume sold short2026-09-11: 68% of volume sold short2026-09-14: 64% of volume sold short2026-09-15: 33% of volume sold short2026-09-16: 25% of volume sold short2026-09-17: 48% of volume sold short2026-09-18: 50% of volume sold short2026-09-21: 45% of volume sold short2026-09-22: 42% of volume sold short2026-09-23: 38% of volume sold short2026-09-24: 42% of volume sold short2026-09-25: 46% of volume sold short2026-09-28: 42% of volume sold short2026-09-29: 49% of volume sold short2026-09-30: 57% of volume sold short2026-10-01: 64% of volume sold short2026-10-02: 76% of volume sold short2026-10-05: 73% of volume sold short2026-10-06: 55% of volume sold short2026-10-07: 64% of volume sold short2026-10-08: 42% of volume sold short2026-10-09: 57% of volume sold short2026-10-12: 47% of volume sold short2026-10-13: 51% of volume sold short2026-10-14: 59% of volume sold short2026-10-15: 42% of volume sold short2026-10-16: 38% of volume sold short2026-10-19: 63% of volume sold short2026-10-20: 64% of volume sold short2026-10-21: 63% of volume sold short2026-10-22: 61% of volume sold short2026-10-23: 34% of volume sold short2026-10-26: 64% of volume sold short2026-10-27: 54% of volume sold short2026-10-28: 53% of volume sold short2026-10-29: 48% of volume sold short2026-10-30: 43% of volume sold short2026-11-02: 65% of volume sold short2026-11-03: 66% of volume sold short2026-11-04: 36% of volume sold short2026-11-05: 36% of volume sold short2026-11-06: 62% of volume sold short2026-11-09: 49% of volume sold short2026-11-10: 44% of volume sold short2026-11-11: 32% of volume sold short2026-11-12: 68% of volume sold short2026-11-13: 56% of volume sold short2026-11-16: 47% of volume sold short2026-11-17: 47% of volume sold short2026-11-18: 32% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 32%20-day average: 50%Prior 2 months: 54%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded SOLV

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Thomas H TubervilleSenate Sold $1,001 - $15,000 May 3, 2024Aug 5, 2026 +32.2%
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +36.2%

What happened after SOLV insiders bought

Each open-market purchase, measured from the day the filing became public, next to the S&P 500 over the same days. Losses included; "pending" means the days haven't passed yet.

Across all stocks →
FiledInsiderBought7 days30 days90 days
Mar 11, 2026Amy McBride WendellDirector$100K -0.8%+1.4% vs S&P-2.7%-3.4% vs S&P+21.9%+12.7% vs S&P

Insiders at Solventum

InsiderBoughtSoldLast filingPast buys beat S&PScore
Amy McBride WendellDirector $100K — May 1, 2026 1 of 1 —
Heather KnightChief Commercial Officer — — Nov 19, 2026 — —
Bryan C. HansonCEO — — Sep 3, 2026 — —
Wayde D. McMillanCFO — — May 15, 2026 — —
Amy LanducciChief Information Officer — — May 15, 2026 — —
Marcela A. KirbergerGeneral Counsel — — May 15, 2026 — —
Paul S. HarringtonChief Supply Chain Officer — — May 15, 2026 — —
Tammy L. GomezChief Human Resources Officer — — May 15, 2026 — —
Mary T. WilcoxChief Accounting Officer — — May 15, 2026 — —
Carrie Smith CoxDirector — — May 1, 2026 — —
Karen J. MayDirector — — May 1, 2026 — —
John H. WeilandDirector — — May 1, 2026 — —
Glenn A. EisenbergDirector — — May 1, 2026 — —
Bernard A. Harris Jr.Director — — May 1, 2026 — —
Carlos AlbanDirector — — May 1, 2026 — —
Susan D. DevoreDirector — — May 1, 2026 — —
Darryl L. WilsonDirector — — May 1, 2026 — —
Elizabeth MilyDirector — — May 1, 2026 — —
Shirley Ann EdwardsDirector — — May 1, 2026 — —

Board links: companies that share insiders with SOLV

Directors and executives who filed Form 4s for SOLV and another company in the last 12 months.

See the map →
  • AXGNAxogen Amy McBride Wendell Director here · Director at AXGN · latest filing Aug 12, 2026
  • BAXBaxter International Amy McBride Wendell Director here · Director at BAX · latest filing May 7, 2026
  • ELVElevance Health Susan D. Devore Director here · Director at ELV · latest filing May 15, 2026
  • ETNEaton Darryl L. Wilson Director here · Director at ETN · latest filing May 8, 2026
  • NEENextEra Energy Darryl L. Wilson Director here · Director at NEE · latest filing May 1, 2026
  • OGNOrganon Carrie Smith Cox Director here · Chair at OGN · latest filing May 1, 2026
  • TXNTexas Instruments Carrie Smith Cox Director here · Director at TXN · latest filing May 14, 2026
  • WATWaters Heather Knight Chief Commercial Officer here · Director at WAT · latest filing Nov 19, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

SOLV stock: common questions

Are Solventum insiders buying SOLV stock?

In the past 12 months, 1 insider reported open-market purchases of SOLV worth $100K. The latest was Director Amy Mcbride Wendell bought $100K of SOLV at $68.03 — first open-market purchase in our records; raises the stake by 41%.

Are Solventum insiders selling SOLV stock?

No. No Solventum insider reported an open-market sale of SOLV in the past 12 months.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is SOLV's P/E ratio?

SOLV trades at about 99.8 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is SOLV's 52-week range?

Over the past year SOLV has traded between $62.49 and $92.44. It last closed at $85.49 on Nov 19, 2026.